Profound Medical AGM Sees 69.8% Turnout, Directors Re-elected with 79.0%–91.5% Support
Profound Medical's annual meeting recorded 25,347,133 common shares (69.754% of outstanding) represented, with shareholders re-electing eight directors by 79.0%–91.5%, appointing PricewaterhouseCoopers as auditor and approving unallocated restricted and deferred share units under its long-term incentive plan. High voter turnout and approvals may strengthen investor confidence in Profound Medical's strategic direction.
1. Meeting Participation and Voting Results
Profound Medical’s annual general and special meeting was held May 13, 2026, with 25,347,133 common shares, representing 69.754% of outstanding stock, represented in person and by proxy. All matters set out in the information circular were approved by the requisite majority of votes cast.
2. Director Elections
Shareholders re-elected all eight nominees to the board of directors, with support ranging from 78.999% for Arthur Rosenthal to 91.495% for Thomas Wellner. Vote withhold percentages varied from 8.505% to 21.001%, reflecting robust overall endorsement.
3. Other Matters
Attendees approved the appointment of PricewaterhouseCoopers LLP as auditor until the next annual meeting and passed an ordinary resolution authorizing all unallocated restricted share units and deferred share units under the long-term incentive plan.